Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Tbo-filgrastim effectively reduces the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, showing similar efficacy to Neupogen across three phase III studies involving 677 patients with breast cancer, lung cancer, and non-Hodgkin lymphoma.
• American Society of Clinical Oncology (ASCO) guidelines support the prophylactic use of tbo-filgrastim to reduce febrile neutropenia risk in cases where the anticipated risk is approximately 20% or higher, in the absence of an equally effective and safe alternative. 4. 93.5% of patients experienced treatment-emergent adverse events (AEs), primarily due to chemotherapy; 27.3% had drug-related AEs.
• Severe drug-related AEs occurred in 2.8% of patients, with serious drug-related AEs in 0.7%, and 0.9% of patients discontinued due to drug-related AEs.
• There is no population types or subgroups information available in the reviewed studies.